DCPH - Deciphera to expand geographic reach and clinical potential of ripretinib

Deciphera Pharmaceuticals (DCPH) intends to expand the market and clinical potential of ripretinib (QINLOCK®) in 2021, the company said in an announcement, issued in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference.CEO of Deciphera, Steve Hoerter commented: “We are focused in 2021 on expanding both the geographic reach for QINLOCK and the potential for this medicine to benefit patients with GIST even earlier in the course of their disease.”In 2H 2021, the company is expecting the top-line Data from a Pivotal Phase 3 Study of QINLOCK® in Patients with Second-line GIST (gastrointestinal stromal tumor) in addition to potential European approval for the therapy in patients with Fourth-line GIST.The company plans to finalize the pivotal development plans for Vimseltinib (DCC-3014) and Rebastinib/paclitaxel in 2H 2021 when it expects to announce updated data from the Phase 1b/2 study for Rebastinib in combination with paclitaxel for patients with endometrial

For further details see:

Deciphera to expand geographic reach and clinical potential of ripretinib